- Analysis
- Barani Krishnan
- 19
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis; and provides contract research for pharmaceutical and biotechnology companies. Pure Biologics S.A. was incorporated in 2010 and is headquartered in Wroclaw, Poland.
Metrics to compare | PUR1 | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipPUR1PeersSector | |
---|---|---|---|---|
P/E Ratio | −1.2x | −5.0x | −0.7x | |
PEG Ratio | −0.03 | −0.05 | 0.00 | |
Price/Book | −10.6x | 2.0x | 2.6x | |
Price / LTM Sales | −5.0x | 11.3x | 3.1x | |
Upside (Analyst Target) | - | 73.2% | 45.9% | |
Fair Value Upside | Unlock | 5.8% | 8.3% | Unlock |